Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tarsus Pharmaceuticals (TARS) Operating Income (2020 - 2025)

Tarsus Pharmaceuticals (TARS) has 6 years of Operating Income data on record, last reported at -$8.0 million in Q4 2025.

  • For Q4 2025, Operating Income rose 67.34% year-over-year to -$8.0 million; the TTM value through Dec 2025 reached -$71.0 million, up 41.14%, while the annual FY2025 figure was -$71.0 million, 41.14% up from the prior year.
  • Operating Income reached -$8.0 million in Q4 2025 per TARS's latest filing, up from -$14.5 million in the prior quarter.
  • Across five years, Operating Income topped out at $10.7 million in Q1 2021 and bottomed at -$44.4 million in Q4 2023.
  • Average Operating Income over 5 years is -$20.5 million, with a median of -$22.5 million recorded in 2022.
  • Peak YoY movement for Operating Income: surged 605.85% in 2021, then crashed 528.27% in 2023.
  • A 5-year view of Operating Income shows it stood at -$14.4 million in 2021, then dropped by 4.24% to -$15.1 million in 2022, then crashed by 195.13% to -$44.4 million in 2023, then surged by 45.06% to -$24.4 million in 2024, then soared by 67.34% to -$8.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Income were -$8.0 million in Q4 2025, -$14.5 million in Q3 2025, and -$22.2 million in Q2 2025.